Trials / Completed
CompletedNCT03470103
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
A Prospective Observational Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 643 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin America for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc.) and are being switched to intravitreal aflibercept injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Use of intravitreal aflibercept in routine clinical practice in Latin America |
Timeline
- Start date
- 2018-03-28
- Primary completion
- 2020-09-21
- Completion
- 2021-01-15
- First posted
- 2018-03-19
- Last updated
- 2021-06-25
Locations
4 sites across 4 countries: Argentina, Colombia, Costa Rica, Mexico
Source: ClinicalTrials.gov record NCT03470103. Inclusion in this directory is not an endorsement.